LET Topical Gel drug recall for CGMP deviations
Edge Pharma is recalling 26,917 syringes of LET Topical Gel nationwide due to current Good Manufacturing Practice (CGMP) deviations. The recall was initiated voluntarily in December 2021.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for CGMP deviations. The source text does not report any illnesses, injuries, or deaths, and the hazard is manufacturing process deficiency rather than a direct safety risk. Per the rubric, manufacturing/quality issues without reported harm and no stated illness/injury reports are typically classified as Moderate (2).
Plain-English summary
Edge Pharma, LLC is recalling LET Topical Gel (Lidocaine HCL / Epinephrine / Tetracaine HCl, 4%/0.05%/0.5%, 3 mL per syringe, Single Dose Syringe for Topical Use) with NDC 05446-0607-01 due to current Good Manufacturing Practice (CGMP) deviations.
Approximately 26,917 syringes were distributed nationwide. The affected product was manufactured with lot codes issued between July 2021 and October 2021, with distribution dates ranging from December 2021 through March 2022.
The recall is classified as FDA Class II and was initiated voluntarily by the firm on December 6, 2021, based on a press release. The recall has been terminated as of June 7, 2023.
Consumers and healthcare providers in possession of affected syringes should stop use and contact Edge Pharma, LLC for further instructions.
The recalled product
- Product
- LET Topical Gel, Lidocaine HCL / Epinepherine / Tetracaine HCl, 4%/0.05%/0.5%, 3 mL per syringe, Single Dose Syringe for Topical Use, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT, NDC 05446-0607-01
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Topical Anesthetic
- Hazard
- cgmp-deviations
- manufacturing-deficiency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- 07-2021-12@6 12-09-2021
- 07-2021-19@7 12-16-2021
- 07-2021-26@5 12-23-2021
- 08-2021-02@8 12-30-2021
- 08-2021-09@10 01-06-2022
- 08-2021-13@6 01-10-2022
- 08-2021-18@4 01-15-2022
- 08-2021-24@8 01-21-2022
- 08-2021-30@5 01-27-2022
- 09-2021-07@11 02-04-2022
- 09-2021-13@5 02-10-2022 & 10-2021-04@9 03-03-2022.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27